StephenTOhMDPhD

PubMed

• 2 citations
  Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.
  Claire N Harrison, Ruben Mesa, Moshe Talpaz, Vikas Gupta, Aaron T Gerds
  Clinical Lymphoma, Myeloma & Leukemia. 2025-03-01
• RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia.
  Tim Kong, Angelo B A Laranjeira, Christopher T Letson, LaYow Yu, Shuyang Lin
  Nature Communications. 2025-01-16
• Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
  Meagan A Jacoby, Eric D Duncavage, Ajay Khanna, Gue Su Chang, Sridhar Nonavinkere Srivatsan
  Leukemia. 2025-01-01

Abstracts/Posters

• Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages
  Stephen T. Oh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry
  Stephen T. Oh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Interrogating the Role of ASXL1 and JAK2 mutations in Myeloproliferative Neoplasms Utilizing Human Pluripotent Stem Cells
  Stephen T. Oh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2Rα but Is High in Patients Treated with Ruxolitinib 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018